Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals has reported Net Cash Flow for 10 years, with the latest figure at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 107.54% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (up 106.43% YoY), and the FY2025 full-year result was -$163.4 million, down 177.94% from the prior year.
• Net Cash Flow for Q1 2026 stood at $12.8 million, up from -$9.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $341.0 million in Q1 2024, with the low at -$170.0 million in Q1 2025.
• Average Net Cash Flow over 5 years is -$5.1 million, with a median of -$9.8 million recorded in 2025.
• Peak annual rise in Net Cash Flow reached 3902.19% in 2024, while the deepest fall reached 5613.71% in 2024.
• Tracing CRNX's Net Cash Flow over 5 years: stood at $1.8 million in 2022, then sank by 5091.37% to -$87.9 million in 2023, then surged by 40.02% to -$52.7 million in 2024, then soared by 81.49% to -$9.8 million in 2025, then soared by 231.29% to $12.8 million in 2026.
• The last three Net Cash Flow figures came in at $12.8 million (Q1 2026), -$9.8 million (Q4 2025), and $57.2 million (Q3 2025), per Business Quant data.

Peer Comparison